Allergy Therapeutics (LON:AGY) Shares Down 10.4% – Time to Sell?

Allergy Therapeutics plc (LON:AGY)’s stock price fell 10.4% during trading on Monday . The stock traded as low as GBX 5.62 ($0.07) and last traded at GBX 6.28 ($0.08). 180,738 shares changed hands during trading, a decline of 66% from the average session volume of 535,030 shares. The stock had previously closed at GBX 7 ($0.09).

Allergy Therapeutics Trading Down 8.9 %

The business’s 50-day moving average is GBX 6.57 and its two-hundred day moving average is GBX 5.43. The stock has a market capitalization of £282.34 million, a PE ratio of -98.65, a PEG ratio of -30.70 and a beta of 1.40. The company has a quick ratio of 1.48, a current ratio of 1.40 and a debt-to-equity ratio of 37.22.

Allergy Therapeutics (LON:AGY) last announced its earnings results on Wednesday, November 6th. The company reported GBX (1.07) (($0.01)) earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative net margin of 94.29% and a negative return on equity of 155.90%. On average, analysts anticipate that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.